Gene Location [1]
Cell cycle control
Variant Type

CDKN2A Amplification is present in 0.09% of AACR GENIE cases, with breast carcinoma, ovarian neoplasm, colorectal adenocarcinoma, small cell lung carcinoma, and prostate cancer having the greatest prevalence [4].

Top Disease Cases with CDKN2A Amplification

Significance of CDKN2A Amplification in Diseases

Cervical Carcinoma +

Oropharyngeal Squamous Cell Carcinoma +

Anal Squamous Cell Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Cervical Squamous Cell Carcinoma +

Penile Carcinoma +

Vaginal Squamous Cell Carcinoma +

Vulvar Squamous Cell Carcinoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.